Arcutis Biotherapeutics Stock Buy Hold or Sell Recommendation
| ARQT Stock | USD 10.77 0.63 6.21% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Arcutis Biotherapeutics is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Arcutis Biotherapeutics given historical horizon and risk tolerance towards Arcutis Biotherapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Arcutis Biotherapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Arcutis Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide. Note, we conduct extensive research on individual companies such as Arcutis and provide practical buy, sell, or hold advice based on investors' constraints. Arcutis Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
Arcutis |
Execute Arcutis Biotherapeutics Buy or Sell Advice
The Arcutis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Arcutis Biotherapeutics. Macroaxis does not own or have any residual interests in Arcutis Biotherapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Arcutis Biotherapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Arcutis Biotherapeutics Trading Alerts and Improvement Suggestions
| Arcutis Biotherapeutics had very high historical volatility over the last 90 days | |
| Arcutis Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 59.61 M. Net Loss for the year was (262.14 M) with profit before overhead, payroll, taxes, and interest of 2.93 M. | |
| Arcutis Biotherapeutics currently holds about 282.17 M in cash with (247.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.47. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Arcutis Biotherapeutics, Inc. Stock Position Increased by Jennison Associates LLC - MarketBeat |
Arcutis Biotherapeutics Returns Distribution Density
The distribution of Arcutis Biotherapeutics' historical returns is an attempt to chart the uncertainty of Arcutis Biotherapeutics' future price movements. The chart of the probability distribution of Arcutis Biotherapeutics daily returns describes the distribution of returns around its average expected value. We use Arcutis Biotherapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Arcutis Biotherapeutics returns is essential to provide solid investment advice for Arcutis Biotherapeutics.
| Mean Return | 0.20 | Value At Risk | -5.44 | Potential Upside | 7.00 | Standard Deviation | 3.54 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Arcutis Biotherapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Arcutis Stock Institutional Investors
The Arcutis Biotherapeutics' institutional investors refer to entities that pool money to purchase Arcutis Biotherapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.5 M | Ensign Peak Advisors Inc | 2024-09-30 | 2.4 M | Cormorant Asset Management, Llc | 2024-09-30 | 2.3 M | Pivotal Bioventure Partners Investment Advisor Llc | 2024-06-30 | 2 M | Deutsche Bank Ag | 2024-06-30 | 1.9 M | Stempoint Capital Lp | 2024-09-30 | 1.8 M | D. E. Shaw & Co Lp | 2024-09-30 | 1.7 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.6 M | J. Goldman & Co Lp | 2024-09-30 | 1.5 M | Jennison Associates Llc | 2024-09-30 | 11.7 M | Suvretta Capital Management, Llc | 2024-06-30 | 10 M |
Arcutis Biotherapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (26.3M) | (181.5M) | (75.0M) | (87.2M) | 284.6M | 298.8M | |
| Change In Cash | 23.9M | 3.3M | 31.4M | (43.1M) | 34.4M | 36.2M | |
| Free Cash Flow | (43.1M) | (113.4M) | (175.6M) | (281.0M) | (247.5M) | (235.1M) | |
| Other Non Cash Items | (354K) | 333K | 309K | 30.3M | (1.8M) | (1.7M) | |
| Net Income | (42.0M) | (135.7M) | (206.4M) | (311.5M) | (262.1M) | (249.0M) | |
| End Period Cash Flow | 63.3M | 66.6M | 98.0M | 54.9M | 89.3M | 65.2M | |
| Change To Netincome | 470K | 8.0M | 23.9M | 63.0M | 72.4M | 76.1M |
Arcutis Biotherapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Arcutis Biotherapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Arcutis Biotherapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Arcutis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.005 | |
β | Beta against Dow Jones | 1.64 | |
σ | Overall volatility | 3.46 | |
Ir | Information ratio | 0.02 |
Arcutis Biotherapeutics Volatility Alert
Arcutis Biotherapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Arcutis Biotherapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Arcutis Biotherapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Arcutis Biotherapeutics Fundamentals Vs Peers
Comparing Arcutis Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Arcutis Biotherapeutics' direct or indirect competition across all of the common fundamentals between Arcutis Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Arcutis Biotherapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Arcutis Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Arcutis Biotherapeutics to competition |
| Fundamentals | Arcutis Biotherapeutics | Peer Average |
| Return On Equity | -1.92 | -0.31 |
| Return On Asset | -0.31 | -0.14 |
| Profit Margin | (1.41) % | (1.27) % |
| Operating Margin | (0.87) % | (5.51) % |
| Current Valuation | 1.06 B | 16.62 B |
| Shares Outstanding | 117.05 M | 571.82 M |
| Shares Owned By Insiders | 2.10 % | 10.09 % |
| Shares Owned By Institutions | 97.90 % | 39.21 % |
| Number Of Shares Shorted | 27.76 M | 4.71 M |
| Price To Book | 7.58 X | 9.51 X |
| Price To Sales | 9.09 X | 11.42 X |
| Revenue | 59.61 M | 9.43 B |
| Gross Profit | 2.93 M | 27.38 B |
| EBITDA | (227.43 M) | 3.9 B |
| Net Income | (262.14 M) | 570.98 M |
| Cash And Equivalents | 282.17 M | 2.7 B |
| Cash Per Share | 5.47 X | 5.01 X |
| Total Debt | 205.92 M | 5.32 B |
| Debt To Equity | 0.40 % | 48.70 % |
| Current Ratio | 10.75 X | 2.16 X |
| Book Value Per Share | 1.34 X | 1.93 K |
| Cash Flow From Operations | (247.06 M) | 971.22 M |
| Short Ratio | 16.78 X | 4.00 X |
| Earnings Per Share | (1.77) X | 3.12 X |
| Price To Earnings To Growth | (0.31) X | 4.89 X |
| Target Price | 19.0 | |
| Number Of Employees | 296 | 18.84 K |
| Beta | 1.19 | -0.15 |
| Market Capitalization | 1.26 B | 19.03 B |
| Total Asset | 341.37 M | 29.47 B |
| Retained Earnings | (981.9 M) | 9.33 B |
| Working Capital | 283.76 M | 1.48 B |
| Current Asset | 87.18 M | 9.34 B |
Note: Acquisition by Matsuda Masaru of 4875 shares of Arcutis Biotherapeutics subject to Rule 16b-3 [view details]
Arcutis Biotherapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Arcutis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Arcutis Biotherapeutics Buy or Sell Advice
When is the right time to buy or sell Arcutis Biotherapeutics? Buying financial instruments such as Arcutis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Arcutis Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 236 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.